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Background
Ipilimumab is an immunotherapy that blocks the function
of an immune checkpoint, cytotoxic T-lymphocyte antigen
4 (CTLA-4), and promotes durable anti-tumor responses
in a subset of patients. We hypothesized that ipilimumab
could be added to androgen deprivation therapy (ADT) as
treatment for patients with metastatic prostate cancer in
an attempt to limit the amount of ADT (8 months) but
provide durable anti-tumor responses. We aimed to corre-
late immunologic biomarkers with clinical responses,
including immune-related adverse events (irAEs).
Methods
We conducted a single-arm, single-center, observational
study from July, 2011 to June, 2013 to determine if finite
ADT plus ipilimumab is safe, estimate efficacy and link
clinical outcomes to immunologic changes in men with
metastatic non-castrate prostate cancer. ADT was admi-
nistered for only 8 months with concurrent ipilimumab
(10 mg/kg) for up to 4 doses at 4-weeks intervals.
Results
We screened 30 pts of which 24 were evaluable for efficacy
and 27 for safety. The median time to PSA progression
was 9.9 (IQR 5.8-13.1) months from treatment initiation,
and two of the 24 (8%) patients have PSA responses that
are ongoing for 40.7 and 17.9 months, respectively. The
trial was closed as pre-specified due to excess toxicity in
which 12 of 27 (44%) patients developed grade 3 immune-
related adverse events (irAEs), which have been observed
with Ipilimumab monotherapy. The most common grade
3 events were transaminitis, colitis/diarrhea, and hypophy-
sitis. Immunological biomarkers were identified that
potentially predict for clinical benefit and grade 3 irAEs.
Conclusions
This pilot study suggests the combination of ipilimumab plus
finite ADT can induce durable responses in a subset of
patients with metastatic prostate cancer. irAEs are likely to
occur and require careful management. Comprehensive
immune monitoring of peripheral blood CD4 and CD8 T
cells by flow cytometry and sequencing the CDR3 region of
the T cell receptor beta chain revealed potential biomarkers
predictive of clinical outcomes. Future studies with lower
doses of ipilimumab may need to be tested in combination
with ADT.
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